Study Comparing Estradiol Vaginal Inserts 4mcg To IMVEXXY ® (Estradiol Vaginal Inerts 4 mcg) In The Treatment Of Dyspareunia in Women With Vulvur and Vaginal Atrophy
NCT ID: NCT05617820
Last Updated: 2024-04-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
1050 participants
INTERVENTIONAL
2022-11-15
2024-03-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Evaluate the Safety and Bioequivalence of Estradiol Vaginal Inserts, 10 mcg and Vagifem® 10 mcg and Compare to Placebo
NCT01779947
TXV13-01 Estradiol Vaginal Softgel Capsules in Treating Postmenopausal Women With Symptoms of Vulvar and Vaginal Atrophy
NCT02449902
Estradiol Vaginal Softgel Capsules in Treating Symptoms of Vulvar and Vaginal Atrophy in Postmenopausal Women
NCT02253173
To Study Generic Estradiol 10 mcg Vaginal Tablets in the Treatment of Vulvar and Vaginal Atrophy in Post Menopausal Women.
NCT02668796
Evaluation of the Acceptability and Efficacy of 10 Micrograms of Estradiol Vaginal Tablets vs Promestriene Vaginal Cream
NCT04232813
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Estradiol vaginal inserts, 4 mcg
Estradiol vaginal inserts, 4 mcg. Insert vaginally once daily for 14 days.
Estradiol
Vaginal Insert, 4 mcg tablet
IMVEXXY® (estradiol vaginal inserts) 4 mcg
IMVEXXY® (estradiol vaginal inserts) 4 mcg. Insert vaginally once for 14 days.
Imvexxy
Estradiol 4 mcg Vaginal Insert
Placebo vaginal inserts
Placebo vaginal inserts. Insert vaginally once for 14 days.
Placebo
Vehicle Vaginal Insert
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Estradiol
Vaginal Insert, 4 mcg tablet
Imvexxy
Estradiol 4 mcg Vaginal Insert
Placebo
Vehicle Vaginal Insert
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Females aged 40-75 years inclusive who are postmenopausal, with at least:
1. 12 months of spontaneous amenorrhea (women \<55 year of age with history of hysterectomy without bilateral oophorectomy prior to natural menopause must have Serum follicle-stimulating hormone (FSH) level \> 40 mIU/mL); or
2. 6 months of spontaneous amenorrhea with FSH levels \>40mIU/mL; or
3. At least 6 weeks postsurgical bilateral oophorectomy
3. Have less than or equal to 5% superficial cells on vaginal cytological smear.
4. Vaginal pH \> 5.0.
5. Moderate to severe symptom of vaginal pain associated with sexual activity considered the most bothersome vaginal symptom (dyspareunia) of VVA by the patient at screening visit. (i.e., a VVA Symptom Self-Assessment Questionnaire score of 2 or 3) (Appendix B).
6. Women should be sexually active (for example, have sexual activity with vaginal penetration within approximately one month of screening visit).
7. Women should anticipate having sexual activity (with vaginal penetration) during the conduct of the study, and agree to at least one episode of sexual intercourse within study days 10-13.
8. Baseline systolic blood pressure should be no greater than 150 mm Hg and diastolic blood pressure no greater than 90 mm Hg.
9. Normal mammogram completed within 9 months before randomization and a normal clinical breast examination prior to randomization in the study.
10. Patients who have underwent complete Hysterectomy, or in the case of patients with an intact uterus (including patients who underwent a partial hysterectomy) the later must have:
1. A documented papanicolaou (PAP) smear conducted within 12 months before randomization with no findings that the Investigator believes would contraindicate the use of topical vaginal estradiol.
2. Documented vaginal ultrasonography results within 3 months before randomization to confirm an inactive endometrial lining, defined as endometrial thickness \<4mm.
11. In the opinion of the Investigator, the patient will comply with the protocol and has a high probability of completing the study.
Exclusion Criteria
2. Significant history or current evidence of chronic infectious disease, system disorder, organ disorder or other medical condition that in the Investigator's opinion would place the study patient at undue risk by participation or could jeopardize the integrity of the study evaluations.
3. Any clinically significant laboratory finding that, in the Investigator's opinion would contraindicate the use of estradiol or compromise patients' safety.
4. Significant history of cholestatic jaundice, hypertension, coronary heart disease or other serious heart problems, uncontrolled diabetes, hypercholesterolemia, hypercalcemia, hypoparathyroidism, hypertriglyceridemia, systemic lupus erythematosus, renal impairment, residual endometriosis posthysterectomy, asthma, epilepsy, migraine, porphyria, hepatic hemangiomas that in the Investigator's opinion would place the study patient at undue risk by participation or could jeopardize the integrity of the study evaluations.
5. History of Protein C, Protein S, or antithrombin deficiency, or other thrombophilic disorder.
6. Patients with known concurrent vaginal infections including but not limited to: Candida albicans, Trichomonas vaginalis, Chlamydia trachomatis, Neisseria gonorrhea or Gardnerella vaginalis.
7. Patients with active vaginal herpes simplex infection or have had an outbreak within 40 days before Screening
8. History of sexual abuse that in the opinion of the investigator may interfere with the patient's assessment of vaginal pain with sexual activity.
9. Past or current diagnosis of endometrial hyperplasia.
10. Patients with known, suspected or current history of carcinoma of the breast.
11. Any patients with past or current undiagnosed vaginal bleeding or significant risk factors for endometrial cancer.
12. History of estrogen-dependent neoplasia (e.g., endometrial cancer).
13. Any patients with hypersensitivity to estrogens.
14. Liver impairment or disease or kidney dysfunction or disorder (e.g., chronic renal failure or hepatitis C).
15. History of thrombophlebitis, thrombosis, or thromboembolic disorders.
16. History of cerebrovascular accident, stroke, or transient ischemic attack.
17. History of Myocardial infarction or ischemic heart disease.
18. History or active presence of endocrine disease (except for controlled hypo- or hyper-thyroidism or controlled non-insulin dependent diabetes mellitus). Patients who are on a stable thyroid medication prior to the study should have normal baseline thyroid function test results and expect not to have to change thyroid hormone regimen during the study.
19. Any clinically significant abnormalities on screening physical exam, assessments, ECG, or laboratory tests such as:
1. Vulvar or vaginal inflammatory condition such as a contact or allergic dermatitis, lichen sclerosis, or other pathological findings.
2. Presence of suspicious vulvar or vaginal lesions for dysplasia, malignancy, or other pathology other than atrophy.
3. History of active or chronic pelvic pain.
4. Painful genital warts or localized areas of ulceration.
5. Interstitial cystitis.
6. Unresolved findings suspicious for malignancy on the breast exam; incomplete mammogram result or unresolved findings suggestive of malignant changes or findings requiring follow-up on the pre-study mammogram.
7. Patients with an intact uterus who have an endometrial thickness of 4mm or greater.
20. Any prescription treatment for vaginal dryness/irritation within 2 weeks before screening or any over the counter or natural remedies, vaginal lubricants or moisturizers within 1 week before screening.
21. Taking inducers of CYP3A4 such as St. John's wort, anticonvulsants, phenylbutazone, rifampin, rifabutin, nevirapine and efavirenz.
22. Taking inhibitors of CYP3A4 such as erythromycin, clarithromycin, ketoconazole, itraconazole, ritonavir, nelfinavir and grapefruit juice.
23. Fasting triglyceride levels \> 350 mg/dL.
24. History of radiation therapy or recent (within previous 6 weeks) surgical therapy to the vaginal or cervical areas.
25. Any known or suspected allergies that in the Investigator's opinion would compromise the safety of the patient.
26. Patients who have used vaginal hormonal products (i.e. rings, creams, gels) within the 4 weeks before Screening.
27. Patients who have used transdermal estrogen and/or progestin therapy within the 4 weeks before Screening.
28. Patients who have used oral estrogen, progestin, androgen or selective estrogen receptor modular (SERM) containing drug products within 8 weeks before Screening visit.
29. Intrauterine progestin therapy within 8 weeks before Screening.
30. Use of an intrauterine device within 12 weeks before screening visit.
31. Patients who have used estrogen pellet therapy or progestin implants/ injectable drug therapy within the 6 months before Screening.
32. Patients who have engaged in sexual intercourse or used vaginal douching within 24 hours of the screening visit.
33. Inability to understand the requirements of the study and the relative information or are unable or not willing to comply with the study protocol.
34. Patients who are unable or unwilling to give informed consent.
35. Current history of heavy smoking (more than 15 cigarettes per day) or use of e-cigarettes.
36. Current use of marijuana.
37. Recent history of known alcohol or drug abuse, within one year start of the study.
38. Employees of the Investigator or research center or their immediate family members.
39. Receipt of any drug as part of a research study within 60 days before Screening.
40. Previous participation in this study.
40 Years
75 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Teva Pharmaceuticals USA
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
C Dias
Role: STUDY_DIRECTOR
Teva Pharmaceuticals USA
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Site 10112
Birmingham, Alabama, United States
Site 10146
Chandler, Arizona, United States
Site 10103
Sacramento, California, United States
Site 10124
Sacramento, California, United States
Site 10135
San Diego, California, United States
Site 10136
Milford, Connecticut, United States
Site 10130
Edgewater, Florida, United States
Site 10123
Hialeah, Florida, United States
Site 10139
Lake Worth, Florida, United States
Site 10115
Leesburg, Florida, United States
Site 10138
Maitland, Florida, United States
Site 10107
Miami Lakes, Florida, United States
Site 10144
Miami Lakes, Florida, United States
Site 10101
Miami Springs, Florida, United States
Site 10106
New Port Richey, Florida, United States
Site 10143
Oldsmar, Florida, United States
Site 10129
Ormond Beach, Florida, United States
Site 10116
Palm Harbor, Florida, United States
Site 10117
Sarasota, Florida, United States
Site 10121
Sunrise, Florida, United States
Site 10140
Tampa, Florida, United States
Site 10119
West Palm Beach, Florida, United States
Site 10113
Norcross, Georgia, United States
Site 10104
Wichita, Kansas, United States
Site 10128
Marrero, Louisiana, United States
Site 10109
Metairie, Louisiana, United States
Site 10122
New Orleans, Louisiana, United States
Site 10105
Saginaw, Michigan, United States
Site 10111
Las Vegas, Nevada, United States
Site 10147
North Las Vegas, Nevada, United States
Site 10126
Lawrenceville, New Jersey, United States
Site 10137
New Bern, North Carolina, United States
Site 10145
New Bern, North Carolina, United States
Site 10134
Philadelphia, Pennsylvania, United States
Site 10102
Upper Saint Clair, Pennsylvania, United States
Site 10110
North Charleston, South Carolina, United States
Site 10118
Chattanooga, Tennessee, United States
Site 10142
Beaumont, Texas, United States
Site 10120
Fort Worth, Texas, United States
Site 10141
Houston, Texas, United States
Site 10108
Norfolk, Virginia, United States
Site 10154
Seattle, Washington, United States
Site 10148
Santa Tecla, La Libertad Department, El Salvador
Site 10149
San Salvador, , El Salvador
Site 10151
San Pedro Sula, , Honduras
Site 10153
San Pedro Sula, , Honduras
Site 10150
San Pedro Sula, , Honduras
Site 10152
San Pedro Sula, , Honduras
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
71836003
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.